Annexon (ANNX) Interest & Investment Income (2021 - 2026)
Annexon (ANNX) posted quarterly Interest & Investment Income of -$53000.0 for Q1 2026, up 47.52% year-over-year from -$35926.2 in Q1 2025, and down 212.77% quarter-over-quarter from $47000.0 in Q4 2025.
Powered by 
Analysis
Annexon (ANNX) Interest & Investment Income (2021 - 2026) Analysis & Trends
Annexon's Interest & Investment Income history runs 6 years deep, the most recent figure standing at -$53000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 47.52% year-over-year to -$53000.0; the TTM figure through Mar 2026 stood at $7000.0 (down 50.0% YoY), while the FY2025 annual figure was -$41000.0, down 153.25% from the prior year.
- Interest & Investment Income for Q1 2026 stood at -$53000.0, down from $47000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $164000.0 in Q3 2024, with the low at -$196000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $17000.0 (2025), against an average of $6176.5.
- Peak annual rise in Interest & Investment Income reached 628.57% in 2022, while the deepest fall reached 684.0% in 2022.
- Annexon's Interest & Investment Income stood at $26000.0 in 2022, then soared by 123.08% to $58000.0 in 2023, then tumbled by 205.17% to -$61000.0 in 2024, then surged by 177.05% to $47000.0 in 2025, then plunged by 212.77% to -$53000.0 in 2026.
- Business Quant data shows ANNX's Interest & Investment Income at -$53000.0 in Q1 2026, $47000.0 in Q4 2025, and $17000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Annexon | 971.85 Mn | 971.85 Mn | - | -1,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | -53,000.00 |
| Dec 31, 2025 | 47,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Jun 30, 2025 | -4,000.00 |
| Mar 31, 2025 | -101,000.00 |
| Dec 31, 2024 | -61,000.00 |
| Sep 30, 2024 | 164,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | -38,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Sep 30, 2023 | 50,000.00 |
| Jun 30, 2023 | 47,000.00 |
| Mar 31, 2023 | 160,000.00 |
| Dec 31, 2022 | 26,000.00 |
| Sep 30, 2022 | 37,000.00 |
| Jun 30, 2022 | -60,000.00 |
| Mar 31, 2022 | -196,000.00 |
| Dec 31, 2021 | -105,000.00 |
| Sep 30, 2021 | -7,000.00 |